ColonoscopyCARE-UAENCT07835542
Triton 1.5 Robotic System for Diagnostic Colonoscopy in the Middle East
A study testing Diagnostic Test: Diagnostic Colonoscopy in people with Colonoscopy and Colorectal Cancer Screening, run by Neptune Medical at 1 site in United Arab Emirates.
Trial summary
The purpose of this study is to gain early experience in the Triton 1.5 System in performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤ 2 cm). Read more about this study
- Who is it for?
- Ages 22 years and olderHealthy volunteers can take part
- Conditions the study is for
- Colonoscopy, Colorectal Cancer Screening
- What is being tested?
- Diagnostic Test: Diagnostic Colonoscopy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited Arab Emirates
- Study dates
- 12 Oct 2026to 12 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 22 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥ 22 years
- Adults indicated for elective screening, surveillance or diagnostic colonoscopy
- Subject is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures
- Subject is willing and able to comply with all protocol required preparation and follow- up visits
Who cannot join
- Any medical or physical condition/limitation that would contraindicate a conventional colonoscopy. This assessment will be made by the investigator.
- Any active or magnetic implantable medical devices (e.g., pacemakers, defibrillators)
- Previous failed colonoscopy (except for inadequate bowel preparation)
- BMI > 45 kg/m2
- Pregnant participants
- Surgically altered colonic anatomy
Show all 23Show fewer
- History of colorectal cancer, inflammatory bowel disease, polyposis syndrome, hereditary nonpolyposis colorectal cancer (Lynch) syndrome, sclerosing encapsulating peritonitis, active diverticulitis in last 6 months or toxic megacolon
- Lower gastrointestinal bleeding within 28 days prior to the colonoscopy day
- Known bleeding tendency such as hemophilia or coagulation factor deficiencies
- Subject receiving antiplatelet or anticoagulation therapy apart from low-dose aspirin
- Known colonic stricture
- Known risk factors for abdominal adhesions such as history of complex abdominal or pelvis surgical procedures, based on investigator assessment
- Known abdominal wall hernias
- History of radiotherapy to the abdomen or pelvis
- History of mesenteric ischemia
- Known coronary ischemia or cardiovascular stroke within 3 months prior to the colonoscopy procedure
- Contraindication to the proposed sedation / anesthesia
- Received any investigational medicine or treatment within 28 days prior to the colonoscopy procedure
- Received or planning to receive any other endoscopic procedure within 4 weeks prior and 2 weeks after the colonoscopy procedure
- Participation in any concurrent clinical trial that may impact the results of this study
- Intra-Operative Criteria:
- Inadequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) (Appendix A) score < 2 in any segment.
- Any intraoperative finding or condition that, in the Investigator's judgment, would make study participation unsafe or not in the subject's best interest (e.g., significant stricture, tight sigmoid colon precluding safe overtube passage).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Arab Emirates1 site
Cleveland Clinical Abu Dhabi
Abu Dhabi, Al Maryah
About this study
Official title: Early Clinical Experience With the Triton 1.5 Robotic System for Diagnostic Colonoscopy in the Middle East
The purpose of this study is to gain early experience in the Triton 1.5 System in performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤ 2 cm). This study will be the first clinical experience with Triton 1.5 in the Middle East, conducted at Cleveland Clinic Abu Dhabi.
Read the detailed description
The study will include up to 10 patients for operator training and familiarization with the Triton 1.5 System. Data from the training phase will be collected for operational and safety review but will not contribute to the primary or secondary endpoint analyses. Up to 20 subjects will undergo robotic colonoscopy to evaluate the performance of Triton 1.5 System in diagnostic, screening, surveillance colonoscopies, which are inclusive of basic therapeutic tasks, such as polypectomy for lesions ≤ 2 cm.
- Conditions
- Colonoscopy, Colorectal Cancer Screening
- Being tested
- Diagnostic Test: Diagnostic Colonoscopy
- Keywords
- Colonoscopy, Colorectal Cancer Screening, Colorectal Neoplasms, Gastrointestinal Endoscopy
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diagnostic Test: Diagnostic ColonoscopyDevice
This study will serve to gain early experience in the Triton 1.5 System in performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤2cm).
| Study group | Role | What they receive |
|---|---|---|
| Single Arm | Other | This study is a prospective, single-arm, non-randomized, single-site study, which is deigned to evaluate the safety and efficacy of the Triton 1.5 System for performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤2cm) during endoscopic procedures. Receives: Device: Diagnostic Test: Diagnostic Colonoscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Safety Endpoint - Incident of Major Adverse Events within 48 Hours
Absence of Major Adverse Events (MAEs) within 48 hours of the procedure. MAEs are defined as the following: (a) Device-related death within 48 hours, (b) Perforation within 48 hours, (c) Intraprocedural bleeding preventing completion of the procedure, (d) Delayed bleeding within 48 hours accompanied by predefined symptoms and confirmed by a hemoglobin drop of >2 g, as applicable, leading to admission to hospital, prolongation of existing hospital stay, another procedure (requiring sedation/anesthesia). Unit of Measure: Number of participants with at least one Major Adverse Event
Measured: 48 Hours
Primary Efficacy Endpoint - Successful Completion of Colonoscopy During Procedure
Completion of colonoscopy defined by both: (a) Successful cecal intubation with visualization of the appendiceal orifice, (b) Successful withdrawal with clinically acceptable diagnostic inspection and therapeutic access.
Measured: During Procedure
Secondary outcomes (9)
Secondary Safety Endpoint - Mucosal Injury Score During Procedure
Mucosal Injury graded using a visual assessment of the colonic wall during withdrawal of the procedure using the following scale: (1) Erythema / Bruising, (2) Mucosal break < 5 mm, (3) Mucosal break > 5 mm, (4) Muscle injury (non-full thickness), (5) Full-thickness injury. Unit of Measure: Score (1-5), higher scores indicate more severe injury
Measured: During Procedure
Secondary Safety Endpoint - Delayed Bleeding Within 14 Days
Delayed bleeding within 14 days, defined as: bleeding within 48 hours accompanied by pre-defined symptoms and confirmed by a hemoglobin drop > 2 g, leading to admission to hospital, prolongation of existing hospital stay, another procedure (requiring sedation/anesthesia).
Measured: 14 days Post-Procedure
Secondary Safety Endpoint - Delayed Perforations Within 14 Days
Delayed perforations within 14 days, defined as: perforations occurring within 14 days post-procedure.
Measured: 14 days Post-Procedure
Secondary Efficacy Endpoint - Time to Cecum During Procedure
Interval from nested-system insertion at the anal verge to first visualization of the appendiceal orifice. Pauses for ancillary or therapeutic tasks (e.g., biopsy, polypectomy ≤ 2 cm, repositioning, prolonged washing) are recorded and subtracted to isolate insertion performance. For polypectomy pauses, time is measured from first polyp visualization to confirmation of retrieval in the specimen trap. Unit of Measure: Minutes or seconds
Measured: During Procedure
Secondary Efficacy Endpoint - Need for Repositioning During Procedure
Number of times a participant was repositioned during the procedure. Unit of Measure: Number of repositioning events
Measured: During Procedure
Secondary Efficacy Endpoint - Polypectomy Success During Procedure
Clinically acceptable polypectomy performed with cold forceps, cold snare, or hot snare leaving no visible residual polyp. Polyps > 2 cm or lesions too complex for diagnostic colonoscopy are excluded and deferred for later advanced therapy.
Measured: During Procedure
Secondary Efficacy Endpoint - NASA Task Load Index (NASA-TLX) Post-Procedure
Physician's subjective workload assessment using the NASA Task Load Index (NASA-TLX), a validated tool consisting of six subscales: Mental Demand, Physical Demand, Temporal Demand, Performance, Effort, and Frustration. Each subscale is scored from 0 to 100 in increments of 5. Higher scores indicate greater perceived workload. Unit of Measure: Composite score (0-600)
Measured: Immediately after Procedure
Secondary Efficacy Endpoint - Adenoma Detection Rate During Procedure
Percentage of subjects with ≥ 1 histologically confirmed adenoma or carcinoma. Unit of Measure: Percentage of participants
Measured: Within 30 days Post-Procedure
Secondary Efficacy Endpoint - Patient-Reported Discomfort
Patient experience during colonoscopy, evaluated by asking the patient the following questions during recovery after the procedure on the same day. Patients are asked two questions: 1. How much of the procedure do you remember or were aware of? (0 = nothing at all, 10 = everything), and 2. During the procedure, how much discomfort or pain did you experience? (0 = none, 10 = worst imaginable)?
Measured: Up to 24 Hours Post-Procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2026
- Study start12 Oct 2026 (estimated)
- Primary completion30 Nov 2026 (estimated)
- Study completion12 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ColonoscopyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Neptune Medical
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- KCRI, Cleveland Clinic Abu Dhabi
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07835542
- Sponsor's protocol ID
- CP-000006
- Acronym
- CARE-UAE
- Status last verified
- Sep 2026
- First submitted
- 11 Sep 2026
- Last updated
- 23 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Clinical Experience With the Triton 1.5 Robotic System for Diagnostic Colonoscopy in the Middle East
- ClinicalTrials.gov ID
- NCT07835542
- Acronym / sponsor ID
- CARE-UAE / CP-000006
- Conditions
- Colonoscopy, Colorectal Cancer Screening
- Keywords
- Colonoscopy, Colorectal Cancer Screening, Colorectal Neoplasms, Gastrointestinal Endoscopy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Neptune MedicalIndustry (pharma, biotech, devices)
- Collaborators
- KCRI, Cleveland Clinic Abu Dhabi
- Study start
- 12 Oct 2026 (estimated)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 12 Dec 2026 (estimated)
- First posted
- 23 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to gain early experience in the Triton 1.5 System in performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤ 2 cm). This study will be the first clinical experience with Triton 1.5 in the Middle East, conducted at Cleveland Clinic Abu Dhabi.
Detailed description
The study will include up to 10 patients for operator training and familiarization with the Triton 1.5 System. Data from the training phase will be collected for operational and safety review but will not contribute to the primary or secondary endpoint analyses. Up to 20 subjects will undergo robotic colonoscopy to evaluate the performance of Triton 1.5 System in diagnostic, screening, surveillance colonoscopies, which are inclusive of basic therapeutic tasks, such as polypectomy for lesions ≤ 2 cm.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single Arm | Other | Device: Diagnostic Test: Diagnostic ColonoscopyThis study is a prospective, single-arm, non-randomized, single-site study, which is deigned to evaluate the safety and efficacy of the Triton 1.5 System for performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤2cm) during endoscopic procedures. |
Who may qualify
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥ 22 years
- Adults indicated for elective screening, surveillance or diagnostic colonoscopy
- Subject is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures
- Subject is willing and able to comply with all protocol required preparation and follow- up visits
Key exclusion criteria (23 listed)
- Any medical or physical condition/limitation that would contraindicate a conventional colonoscopy. This assessment will be made by the investigator.
- Any active or magnetic implantable medical devices (e.g., pacemakers, defibrillators)
- Previous failed colonoscopy (except for inadequate bowel preparation)
- BMI > 45 kg/m2
- Pregnant participants
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diagnostic Test: Diagnostic ColonoscopyThis study will serve to gain early experience in the Triton 1.5 System in performing diagnostic, screening, surveillance, and basic therapeutic tasks (e.g., polypectomy for lesions ≤2cm). | Device | Single Arm |
Primary outcome
Primary Safety Endpoint - Incident of Major Adverse Events within 48 Hours
Time frame: 48 Hours
Absence of Major Adverse Events (MAEs) within 48 hours of the procedure. MAEs are defined as the following: (a) Device-related death within 48 hours, (b) Perforation within 48 hours, (c) Intraprocedural bleeding preventing completion of the procedure, (d) Delayed bleeding within 48 hours accompanied by predefined symptoms and confirmed by a hemoglobin drop of >2 g, as applicable, leading to admission to hospital, prolongation of existing hospital stay, another procedure (requiring sedation/anesthesia). Unit of Measure: Number of participants with at least one Major Adverse Event
Primary Efficacy Endpoint - Successful Completion of Colonoscopy During Procedure
Time frame: During Procedure
Completion of colonoscopy defined by both: (a) Successful cecal intubation with visualization of the appendiceal orifice, (b) Successful withdrawal with clinically acceptable diagnostic inspection and therapeutic access.
9 secondary outcomes
Secondary Safety Endpoint - Mucosal Injury Score During Procedure
Time frame: During Procedure
Secondary Safety Endpoint - Delayed Bleeding Within 14 Days
Time frame: 14 days Post-Procedure
Secondary Safety Endpoint - Delayed Perforations Within 14 Days
Time frame: 14 days Post-Procedure
Secondary Efficacy Endpoint - Time to Cecum During Procedure
Time frame: During Procedure
Secondary Efficacy Endpoint - Need for Repositioning During Procedure
Time frame: During Procedure
Secondary Efficacy Endpoint - Polypectomy Success During Procedure
Time frame: During Procedure
Secondary Efficacy Endpoint - NASA Task Load Index (NASA-TLX) Post-Procedure
Time frame: Immediately after Procedure
Secondary Efficacy Endpoint - Adenoma Detection Rate During Procedure
Time frame: Within 30 days Post-Procedure
Secondary Efficacy Endpoint - Patient-Reported Discomfort
Time frame: Up to 24 Hours Post-Procedure
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Colonoscopy
Not yet recruiting
Enhanced Ward Rounds for Bowel Preparation Quality in Hospitalized Patients Undergoing Colonoscopy
Colonoscopy, Bowel Preparation
Recruiting
Comparison of Electrolyte Beverages and Water as Solvents for Bowel Preparation
Bowel Preparation Before Colonoscopy
Enrolling by invitation
The Effect of Virtual Reality Application on Pain, Anxiety, and Embarrassment During Colonoscopy
Colonoscopy
Recruiting
Comparison of the Performance Between Conventional Colonoscopy and 3D Colonoscopy in Positive Fecal Immunochemical Test Group
Adenoma Detection Rate, Colonoscopy
Recruiting
Comparison of Adenoma Detection Rate in 3D vs. 2D Surveillance Colonoscopy
Colonoscopy, Adenoma Detection Rate
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Diagnostic Test: Diagnostic Colonoscopy in people with Colonoscopy and Colorectal Cancer Screening, run by Neptune Medical at 1 site in United Arab Emirates.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 23 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Arab Emirates. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hayley Holm ((650) 922-5512, hayley.holm@neptunemedical.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Safety Endpoint - Incident of Major Adverse Events within 48 Hours (time frame: 48 Hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.